AbbVie
ABBV
#29
Rank
NZ$838.86 B
Marketcap
NZ$474.71
Share price
-2.07%
Change (1 day)
17.92%
Change (1 year)

The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol โ€œABBVโ€.

EPS for AbbVie (ABBV)

EPS in 2026 (TTM): NZ$6.24

According to AbbVie's latest financial reports the company's current EPS (TTM) is NZ$6.38. In 2025 the company made an earnings per share (EPS) of NZ$4.27 a decrease over its 2024 EPS that were of NZ$4.33.

EPS history for AbbVie from 2013 to 2026

Annual EPS

Year EPS Change
2026 (TTM)NZ$6.2446.1%
2025NZ$4.27-1.26%
2024NZ$4.33-11.86%
2023NZ$4.91-58.95%
2022NZ$11.962.49%
2021NZ$11.67121.58%
2020NZ$5.27-44.7%
2019NZ$9.5245.84%
2018NZ$6.539.72%
2017NZ$5.95-9.54%
2016NZ$6.5816.28%
2015NZ$5.66184.1%
2014NZ$1.99-57.15%
2013NZ$4.65

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
NZ$1.36-78.71%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
NZ$53.38 736.97%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
NZ$28.97 354.28%๐Ÿ‡บ๐Ÿ‡ธ USA
Biogen
BIIB
NZ$10.15 59.08%๐Ÿ‡บ๐Ÿ‡ธ USA
Gilead Sciences
GILD
NZ-$4.64-172.82%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
NZ$8.11 27.15%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
NZ$11.93 87.09%๐Ÿ‡ฌ๐Ÿ‡ง UK
GSK plc
GSK
NZ$5.71-10.44%๐Ÿ‡ฌ๐Ÿ‡ง UK
Neurocrine Biosciences
NBIX
NZ$12.59 97.45%๐Ÿ‡บ๐Ÿ‡ธ USA